CRISPR Therapeutics AG (CRSP) — Analysis Summary
CRISPR Therapeutics AG (CRSP) has a market cap of $5.23B with year-over-year revenue growth of -90.6%. Net margin stands at -16569.8%. The stock trades at a P/E ratio of -9.2.
Key Takeaways
- Revenue changed -90.6% year-over-year
- Net margin of -16569.8%
- P/E ratio of -9.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CRSP posted revenue growth of -90.6% and trades at a P/E of -9.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.